HOSPITAL UNIVERSITARIO RUBER
Departamento
University of Hasselt
Hasselt, BélgicaPublicaciones en colaboración con investigadores/as de University of Hasselt (1)
2023
-
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2988-2997